Deep Genomics

Deep Genomics is a biopharmaceutical company that leverages artificial intelligence (AI) to revolutionize drug development by decoding RNA biology. Their proprietary AI platform, called the AI Workbench, enables them to identify novel targets, mechanisms, and molecules that are not accessible through traditional methods. This technology helps them develop steric-blocking oligonucleotides (SBOs) for the treatment of genetic diseases. Founded in 2015, Deep Genomics has a multidisciplinary team with expertise in various fields, including AI, software engineering, and laboratory automation.

Deep Genomics is committed to expanding its AI Workbench and scaling its pipeline to 30 programs, including addressing more complex and common diseases. They are also actively advancing four programs into the clinic by 2023, and further establishing their clinical development capabilities. Their strategic geographical advantage is leveraged by combining teams in Toronto, the birthplace of deep learning, with the Boston-Cambridge biotechnology hub. Deep Genomics is committed to building a culture that values a deep, shared understanding of AI, software engineering, and RNA biology.

Deep Genomics offers employees a range of flexible work options, including the ability to work from home, extended long weekends, and flexible vacation time. They also provide a friendly, diverse, and mission-driven culture, and host quarterly social events.

Deep Genomics offers competitive compensation, including meaningful stock ownership, health, vision and dental coverage for employees and families, flexible vacation time, and opportunities to work from home. They also provide extended long weekends, quarterly social events, and a friendly, diverse, mission/value-driven culture. Their facilities are located in the heart of Toronto, the epicenter of machine learning and AI research and development, and in Kendall Square, Cambridge, Mass., a global center of biotechnology and life sciences.

Deep Genomics is a biopharmaceutical company that leverages artificial intelligence (AI) to revolutionize drug development by decoding the complex world of RNA biology. Their proprietary AI platform, called the AI Workbench, enables them to identify novel targets, mechanisms, and molecules that are inaccessible through traditional methods. By using this advanced technology to develop steric-blocking oligonucleotides (SBOs), they aim to provide expression increase for the treatment of a wide range of genetic diseases, ultimately bringing life-changing therapies to patients.

Deep Genomics promotes a collaborative and ambitious culture, attracting top talent from diverse backgrounds in AI, software engineering, and RNA biology. The company prioritizes a culture of innovation, valuing a shared understanding across disciplines and fostering open communication between its medical and life science experts and technical engineers. This approach aims to drive the development of novel solutions at the intersection of AI and biology.

Deep Genomics fosters a welcoming and inclusive culture by actively recruiting from a diverse pool of top talent, including recent graduates and seasoned experts at the intersection of genomics, drug development, and AI. This commitment to diversity extends beyond the recruitment stage, with the company aiming to create an environment where individuals from various backgrounds can thrive, contribute their unique perspectives, and feel valued for their individual contributions.